Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots.
Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots.
复制标题
DOI：
10.1016/j.ebiom.2021.103586
复制
发表时间：
2021-10
期刊：
影响因子：
11.1
通讯作者：
Juno JA
中科院分区：
文献类型：
--
作者：
Kent SJ;Juno JA
COVID-19 感染和 SARS-CoV-2 疫苗接种所引发的免疫力可以有效地启动免疫系统，并提供防止未来再次感染的保护。多项 3 期临床试验的分析表明，中和抗体滴度与防止再次感染的保护作用密切相关[1]。随着时间的推移，中和抗体逐渐减弱 [2]，并且越来越多地报道既往患有 COVID-19 的个体再次感染 [3]。再次感染的临床症状通常较轻，病毒水平较低且传播减少。值得关注的 SARS-CoV-2 变体，尤其是 Beta 和 Delta，传染性更强，并且可以逃避先前感染产生的大部分中和抗体反应 [4]。人们越来越关注为既往感染过 COVID-19 的受试者接种疫苗以防止再次感染。在本文中，Zollner 等人。研究了 14 名既往患有轻中度 COVID-19 且接受 BioNTech/辉瑞 BNT162b2 (Comirnaty) 疫苗的受试者与 27 名未感染受试者相比的抗体和 T 细胞反应[5]。与之前的研究一致，在既往接种过 COVID-19 的受试者中观察到 Spike 特异性中和抗体显着增强，与未感染的对照相比，第一剂后的水平高出 20 倍，第二剂后的水平高出 6 倍。重要的是，对于先前感染的受试者，以标准 3 周间隔接种第 2 剂疫苗的额外益处不大（< 2 倍上升）。这些数据表明，推迟对先前感染过的个体进行第二次疫苗接种可能是重新提高某些人群中和抗体滴度的更具成本效益的策略。尽管它面临着后勤方面的挑战（确认先前的感染），但这样的疫苗-
Immunity elicited by both COVID-19 infection and SARS-CoV-2 vaccination effectively primes the immune system and provides protection from future re-infection. Analysis of multiple phase 3 clinical trials has suggested that neutralizing antibody titres are a strong correlate of protection against re-infection [1]. As time passes, neutralizing antibodies wane [2] and reinfections of individuals with prior COVID-19 are increasingly being reported [3]. Re-infections are generally clinically mild with lower levels of virus and reduced transmission. SARS-CoV-2 variants of concern, in particular Beta and Delta, are more infectious and evade a substantial proportion of the neutralizing antibody response from prior infection [4]. There is increasing interest in vaccination of subjects with prior COVID-19 to prevent reinfections.In this article, Zollner et al. study antibody and T cell responses in a cohort of 14 subjects with prior mild-moderate COVID-19 who received the BioNTech/Pfizer BNT162b2 (Comirnaty) vaccine compared to 27 uninfected subjects [5]. In concordance with prior studies, a remarkable boost in Spike-specific neutralizing antibodies was observed in vaccinated subjects with prior COVID-19, with levels» 20-fold higher after the first dose and» 6-fold higher after the second dose compared to uninfected controls. Importantly, the added benefit of a 2nd vaccine dose at the standard 3-week interval was modest in previously infected subjects (< 2-fold rise). These data suggest that deferring the second vaccination of individuals with prior infection may be a more cost-effective strategy to re-boost neutralizing antibody titres in some populations. Although it comes with logistic challenges (confirming prior infection), such a vaccine-
登录
查看更多内容
影响因子：
16.6
作者：
Wheatley AK;Juno JA;Wang JJ;Selva KJ;Reynaldi A;Tan HX;Lee WS;Wragg KM;Kelly HG;Esterbauer R;Davis SK;Kent HE;Mordant FL;Schlub TE;Gordon DL;Khoury DS;Subbarao K;Cromer D;Gordon TP;Chung AW;Davenport MP;Kent SJ
通讯作者：
Kent SJ
DOI：
10.1038/s41577-021-00550-x
发表时间：
2021-06
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Cromer D;Juno JA;Khoury D;Reynaldi A;Wheatley AK;Kent SJ;Davenport MP
通讯作者：
Davenport MP
影响因子：
82.9
作者：
Juno, Jennifer A.;Tan, Hyon-Xhi;Wheatley, Adam K.
通讯作者：
Wheatley, Adam K.
影响因子：
82.9
作者：
Khoury, David S.;Cromer, Deborah;Davenport, Miles P.
通讯作者：
Davenport, Miles P.
影响因子：
11.1
作者：
Zollner A;Watschinger C;Rössler A;Farcet MR;Penner A;Böhm V;Kiechl SJ;Stampfel G;Hintenberger R;Tilg H;Koch R;Antlanger M;Kreil TR;Kimpel J;Moschen AR
通讯作者：
Moschen AR